Development of a blood-based diagnostic method for Alzheimer's disease with Eisai Co.,Ltd.
First written in FY2020-Q3. 5 of 8 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2024.
3 other companies' latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「January 2024: Following Japan and the United States, the company expanded sales of an Aβ assay reagent in Europe that examines the accumulation of Aβ in the brain, considered a cause of Alzheimer’s disease, using a small blood sample.」
The sales region for the amyloid-beta assay for blood-based Alzheimer’s disease diagnosis has been expanded to Europe. - FY2024-Q1AdvancedAnnual report
「③ June 2023: We launched in Japan the HISCL™ β-Amyloid 1-42 Reagent and HISCL™ β-Amyloid 1-40 Reagent, which examine the accumulation of amyloid beta (Aβ) in the brain, a cause of Alzheimer’s disease, using a blood sample.」
The blood-based diagnostic method for Alzheimer’s disease, developed through joint development and other activities with Eisai Co.,Ltd., has reached the domestic launch of the amyloid-beta assay. - FY2023RestatedAnnual report
「The company also obtained marketing approval in Japan for a test reagent that examines the accumulation of amyloid beta (Aβ) in the brain, a cause of Alzheimer’s disease, using a small blood sample.」
The domestic manufacturing and marketing approval for the HISCL blood amyloid-beta assay has been reposted as progress in developing a blood-based diagnostic method for Alzheimer’s disease with Eisai Co.,Ltd. - FY2022AdvancedAnnual report
「In December 2021, we submitted an application for marketing approval of a testing reagent that measures amyloid beta in blood using the HISCL-5000/HISCL-800 Fully Automated Immunoassay Systems and assists in assessing amyloid beta accumulation in the brain.」
Following the presentation of research results on the blood-based Alzheimer’s disease diagnostic method jointly developed with Eisai Co.,Ltd., the company filed an application for marketing approval of an amyloid beta assay reagent for use with HISCL. - FY2021AdvancedAnnual report
「In March 2021, the company presented the latest data on a blood-based diagnostic method for Alzheimer’s disease being jointly developed with Eisai Co.,Ltd. at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases.」
Following the presentation at the 13th Clinical Trials on Alzheimer’s Disease conference, the company also presented the latest data at the 15th conference. - FY2021-Q3AdvancedAnnual report
「November 2020: We presented the latest data at the 13th Clinical Trials on Alzheimer’s Disease conference on a plasma-based diagnostic method for Alzheimer’s disease being jointly developed by our Company and Eisai Co.,Ltd.」
Following the previous academic report on the joint development with Eisai Co.,Ltd., the company presented the latest data at the 13th Clinical Trials on Alzheimer’s Disease conference. - FY2020RestatedAnnual report
「The company and Eisai Co.,Ltd. will continue working to create new diagnostic technologies for the prevention and treatment of dementia.」
Restates the policy of continuing to create new diagnostic technologies after the academic report on the blood-based Alzheimer’s disease diagnostic method with Eisai Co.,Ltd. - FY2020-Q3First statedAnnual report
「Against this backdrop, the company presented an academic report at the 12th Clinical Trials on Alzheimer’s Disease conference (CTAD) on the development, jointly with Eisai Co.,Ltd., of a blood-based diagnostic method for Alzheimer’s disease. At CTAD, the company announced that its findings suggested the possibility of assessing amyloid pathology in the brain from plasma amyloid beta (Aβ) measured using its HISCL™ series of fully automated immunoassay systems, its protein measurement platform.」
An academic report on the blood-based Alzheimer’s disease diagnostic method jointly developed with Eisai Co.,Ltd. indicated the potential to assess amyloid pathology in the brain from plasma Aβ measured using the HISCL™ series.